Naturo Indiabull (BSE 543579)₹2.61−0.38%Personal Care
In the Sep 2025 quarter (standalone), Naturo Indiabull reported sales of ₹0 Cr, down 100.0% from Sep 2024, and net profit of −₹0.19 Cr, down 139.6% year on year. For the year to Mar 2026, sales were ₹0 Cr and net profit −₹0.81 Cr.
Company filings, standalone accounts; latest reported quarter Sep 2025
| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Sales | 5.77 | 10.45 | 28.83 | 13.20 | 13.42 | 0.00 |
| Expenses | 5.24 | 9.40 | 27.83 | 12.71 | 12.89 | 0.17 |
| Operating Profit | 0.53 | 1.04 | 0.98 | 0.47 | 0.54 | −0.15 |
| OPM % | 9.4% | 10.1% | 3.4% | 3.6% | 4.1% | — |
| Other Income | 0.00 | 0.11 | 0.03 | 0.23 | 0.00 | 0.00 |
| Interest | 0.00 | 0.04 | 0.03 | 0.03 | 0.05 | 0.03 |
| Depreciation | 0.06 | 0.21 | 0.19 | 0.27 | 0.00 | 0.00 |
| Profit before tax | 0.48 | 0.89 | 0.76 | 0.37 | 0.48 | −0.19 |
| Tax % | 20.4% | 26.7% | 0.0% | 39.5% | 0.0% | 0.0% |
| Net Profit | 0.38 | 0.64 | 0.75 | 0.22 | 0.48 | −0.19 |
| EPS (Rs) | 0.39 | 0.65 | 0.76 | 0.13 | 0.27 | −0.12 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 8.26 | 7.03 | 11.31 | 16.22 | 42.03 | 2.06 | 0.00 |
| Expenses | 0.08 | 7.22 | 5.94 | 8.59 | 14.62 | 40.52 | 2.70 | 0.30 |
| Operating Profit | −0.06 | 1.03 | 1.08 | 2.71 | 1.59 | 1.46 | −0.63 | −0.28 |
| OPM % | — | 12.6% | 15.5% | 24.1% | 9.9% | 3.5% | −31.2% | — |
| Other Income | 0.00 | 0.00 | 0.00 | −1.24 | 0.11 | 0.25 | 0.02 | 0.00 |
| Interest | 0.00 | 0.01 | 0.00 | 0.00 | 0.05 | 0.07 | 0.12 | 0.07 |
| Depreciation | 0.00 | 0.02 | 0.01 | 0.05 | 0.26 | 0.47 | 0.62 | 0.44 |
| Profit before tax | −0.06 | 1.00 | 1.05 | 1.44 | 1.38 | 1.14 | −1.38 | −0.81 |
| Tax % | 0.0% | 23.8% | 30.2% | 25.5% | 25.2% | 13.1% | −6.5% | 0.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | −1.04 | 0.00 | 0.15 | 0.00 | 0.00 |
| Net Profit | −0.06 | 0.76 | 0.74 | 1.07 | 1.03 | 0.98 | −1.29 | −0.81 |
| EPS (Rs) | −70.04 | 154.08 | 28.87 | 1.66 | 1.03 | 0.53 | −0.70 | −0.44 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.05 | 0.26 | 6.58 | 10.22 | 18.86 |
| Reserves | 0.00 | −0.07 | 0.71 | 6.74 | 5.88 | 14.22 | 19.55 |
| Borrowings | 2.14 | 2.14 | 2.21 | 1.61 | 0.21 | 3.42 | 12.14 |
| Other Liabilities | 0.01 | 0.08 | 6.58 | 4.57 | 0.83 | 1.19 | 41.79 |
| Total Liabilities | 2.16 | 2.16 | 9.55 | 13.18 | 13.50 | 29.05 | 92.34 |
| Fixed Assets | 0.00 | 0.00 | 0.05 | 0.03 | 0.26 | 1.09 | 1.97 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 |
| Investments | 2.14 | 2.14 | 2.14 | 2.14 | 0.02 | 0.00 | 0.00 |
| Other Assets | 0.02 | 0.02 | 7.36 | 10.92 | 13.13 | 27.87 | 90.28 |
| Inventories | 0.00 | 0.00 | 1.01 | 1.01 | 3.01 | 6.02 | 11.03 |
| Trade receivables | 0.00 | 0.00 | 4.98 | 7.97 | 3.99 | 7.98 | 11.95 |
| Cash & equivalents | 0.00 | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 2.16 | 2.16 | 9.55 | 13.18 | 13.50 | 29.05 | 92.34 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 0.00 | 0.52 | −5.33 | −4.79 | −12.69 | −20.57 | 3.77 | 0.37 |
| Cash from investing activity | −2.12 | 0.00 | −0.03 | −0.09 | 1.83 | −1.06 | −1.12 | −0.11 | 0.00 |
| Cash from financing activity | 2.12 | 0.00 | 0.11 | 4.84 | 2.95 | 14.04 | 21.63 | −3.83 | −0.47 |
| Net cash flow | 0.00 | 0.02 | 0.62 | −0.60 | 0.02 | 0.31 | −0.07 | −0.20 | −0.10 |
| Capex | 0.00 | 0.00 | 0.03 | 0.10 | 0.28 | 1.09 | 1.37 | 0.13 | 0.00 |
| Free cash flow | −0.02 | 0.02 | 0.48 | −5.44 | −5.06 | −13.79 | −21.72 | 3.65 | 0.37 |
| CFO / OP % | — | −14.1% | 50.9% | −490.0% | −176.1% | −794.0% | −1,400.1% | −591.0% | −131.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor days | — | 217 | 411 | 135 | 175 | 100 |
| Inventory days | — | 94 | 55 | 154 | 165 | 99 |
| Days payable | — | 66 | 52 | 10 | 4 | 266 |
| Cash conversion cycle | — | 245 | 413 | 278 | 335 | −68 |
| Working capital days | — | 7 | 244 | 388 | 525 | 323 |
| ROCE % | −3.4% | 40.9% | 18.5% | 26.8% | 7.2% | 2.5% |
For the Sep 2025 quarter, Naturo Indiabull reported sales of ₹0 Cr, down 100.0% year on year and net profit of −₹0.19 Cr, down 139.6% year on year.
Naturo Indiabull's sales for the year to Mar 2026 were ₹0 Cr.
Net profit for the year to Mar 2026 was −₹0.81 Cr. Earnings per share over the same trailing period were ₹−0.44.
Naturo Indiabull reported borrowings of ₹12.14 Cr at Mar 2024, against cash and equivalents of ₹0 Cr.
Cash from operations was ₹0.37 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0.37 Cr.